Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Cosmo Daisey who wrote (796)	3/29/1998 10:21:00 PM
From: dper	Respond to of 9523

<Pfizer is carefully marketing the drug...... > Marketing, maybe, but once a drug is available for any indication, it is often, legally if not ethically, prescribed for off label purposes. And it's not much of a stretch to extend to "relative" erectile dysfunction. After all, the diagnosis is made by obtaining history, not by applying turgidometer. Drugs of this class (I'm sure this won't be the last) will flesh out (pun not intended) the diagnosis of ED. The next variation (son of Viagra) may just use the extended indication (incomplete ED) as a marketing distinction. dper